WST Stock Analysis: West Pharmaceutical | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 25.026m USD | 12M Return: 28.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 272M
EPS Trend: 3.6%
Qual. Beats: 6
Rev. Trend: 77.3%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
West Pharmaceutical Services, Inc. (NYSE: WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products, operating globally across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company runs through two business segments: Proprietary Products and Contract-Manufactured Products. Founded in 1923 and headquartered in Exton, Pennsylvania, West has been publicly traded since its 1978 IPO and is classified as a large-cap stock in the Health Care Supplies sub-industry.
The Proprietary Products segment is the higher-value portion of the business, offering stoppers, seals, syringe and cartridge components, self-injection devices, and integrated drug containment solutions such as vials. It also provides pre-approval packaging support, analytical lab services, regulatory expertise, and after-sales technical support, serving biologic, generic, and pharmaceutical drug developers. Primary packaging components like elastomeric stoppers and seals are a regulated, mission-critical part of the injectable drug supply chain, since they directly affect product sterility, stability, and shelf life.
The Contract-Manufactured Products segment designs, manufactures, and assembles devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as certain consumer products, primarily serving pharmaceutical, diagnostic, and medical device companies. West sells through a combination of its own sales force, distribution network, contract sales agents, and regional distributors. Operating both proprietary and contract manufacturing businesses allows the company to capture high-margin revenue from its own IP while leveraging shared production capabilities for third-party medical device customers.
- GLP-1 injectable demand lifts high-value containment revenue
- Proprietary Products margin expansion outpaces Contract segment
- Capacity expansion capex pressures near-term free cash flow
| Net Income: 564.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.02 > 1.0 |
| NWC/Revenue: 35.08% < 20% (prev 36.36%; Δ -1.28% < -1%) |
| CFO/TA 0.16 > 3% & CFO 662.2m > Net Income 564.9m |
| Net Debt (-10.3m) to EBITDA (810.9m): -0.01 < 3 |
| Current Ratio: 2.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.3m) vs 12m ago -2.06% < -2% |
| Gross Margin: 36.77% > 18% (prev 35.32%; Δ 1.44% > 0.5%) |
| Asset Turnover: 82.86% > 50% (prev 74.88%; Δ 7.98% > 0%) |
| Interest Coverage Ratio: 1.14k > 6 (EBIT TTM 686.5m / Interest Expense TTM 600k) |
| A: 0.29 (Total Current Assets 1.81b - Total Current Liabilities 640.5m) / Total Assets 4.08b |
| B: 1.13 (Retained Earnings 4.62b / Total Assets 4.08b) |
| C: 0.17 (EBIT TTM 686.5m / Avg Total Assets 4.01b) |
| D: 2.75 (Book Value of Equity 2.99b / Total Liabilities 1.09b) |
| Altman-Z'' = 9.62 = AAA |
| DSRI: 1.09 (Receivables 712.0m/582.4m, Revenue 3.33b/2.96b) |
| GMI: 0.96 (GM 35.32% / 36.77%) |
| AQI: -2.36 (AQ_t -0.27 / AQ_t-1 0.11) |
| SGI: 1.12 (Revenue 3.33b / 2.96b) |
| TATA: -0.02 (NI 564.9m - CFO 662.2m) / TA 4.08b) |
| Beneish M = -4.90 (Cap -4..+1) = AAA |
As of July 28, 2026, the stock is trading at USD 331.25 with a total of 1,604,830 shares traded. Over the past week, the price has changed by -5.98%, over one month by -6.61%, over three months by +9.70% and over the past year by +28.94%.
Current recommended Stop Loss: 315.00 (which is 4.9% or 1.4 ATR below the current price).
West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 385.3 | 16.3% |
P/E Trailing = 47.8439
P/E Forward = 41.6667
P/S = 7.7696
P/B = 8.4674
P/EG = 3.4483
Revenue TTM = 3.33b USD
EBIT TTM = 686.5m USD
EBITDA TTM = 810.9m USD
Long Term Debt = 202.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.9m USD (from shortTermDebt, last quarter)
Debt = 425.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 113.4m
Net Debt = -10.3m USD (calculated: Debt 425.5m - CCE 435.8m)
Enterprise Value = 25.0b USD (25.0b + Debt 425.5m - CCE 435.8m)
Interest Coverage Ratio = 1.14k (Ebit TTM 686.5m / Interest Expense TTM 600k)
EV/FCF = 57.26x (Enterprise Value 25.0b / FCF TTM 436.9m)
FCF Yield = 1.75% (FCF TTM 436.9m / Enterprise Value 25.0b)
FCF Margin = 13.13% (FCF TTM 436.9m / Revenue TTM 3.33b)
Net Margin = 16.98% (Net Income TTM 564.9m / Revenue TTM 3.33b)
Gross Margin = 36.77% ((Revenue TTM 3.33b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 37.74% (prev 35.08%)
Tobins Q-Ratio = 6.14 (Enterprise Value 25.0b / Total Assets 4.08b)
Interest Expense / Debt = 0.14% (Interest Expense 600k / Debt 425.5m)
Taxrate = 20.61% (144.2m / 699.6m)
NOPAT = 545.0m (EBIT 686.5m * (1 - 20.61%))
Current Ratio = 2.82 (Total Current Assets 1.81b / Total Current Liabilities 640.5m)
Debt / Equity = 0.14 (Debt 425.5m / totalStockholderEquity, last quarter 2.99b)
Debt / EBITDA = -0.01 (Net Debt -10.3m / EBITDA 810.9m)
Debt / FCF = -0.02 (Net Debt -10.3m / FCF TTM 436.9m)
Total Stockholder Equity = 3.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.07% (Net Income 564.9m / Total Assets 4.08b)
RoE = 18.51% (Net Income TTM 564.9m / Total Stockholder Equity 3.05b)
RoCE = 21.09% (EBIT 686.5m / Capital Employed (Equity 3.05b + L.T.Debt 202.8m))
RoIC = 16.56% (NOPAT 545.0m / Invested Capital 3.29b)
WACC = 6.88% (E(25.0b)/V(25.5b) * Re(6.99%) + D(425.5m)/V(25.5b) * Rd(0.14%) * (1-Tc(0.21)))
Discount Rate = 6.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.87 | Cagr: -1.82%
[DCF] Terminal Value 77.97% ; FCFF base≈399.7m ; Y1≈458.2m ; Y5≈674.4m
[DCF] Fair Price = 144.3 (EV 10.1b - Net Debt -10.3m = Equity 10.2b / Shares 70.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 3.64 | EPS CAGR: 0.34% | SUE: 1.46 | # QB: 6
Revenue Correlation: 77.26 | Revenue CAGR: 4.09% | SUE: 1.17 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.12 | Chg30d=+0.01% | Revisions=-40% | Analysts=11
EPS current Year (2026-12-31): EPS=8.62 | Chg30d=+0.06% | Revisions=+0% | GrowthEPS=+18.2% | GrowthRev=+8.4%
EPS next Year (2027-12-31): EPS=9.62 | Chg30d=+0.66% | Revisions=+0% | GrowthEPS=+11.7% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -22% (up=2, down=4)